Firebrick Pharma(ASX) FRE

Firebrick Pharma Limited is a Melbourne-based healthcare company focused on the research, development, and commercialization of Nasodine, a nasal spray treatment for the common cold. Established in 2012, the company aims to address unmet medical needs in the Australian market.

Products and Services

• Nasodine: A nasal spray designed to treat the common cold
• Research and development initiatives targeting respiratory health
• Potential future products in the pipeline for broader healthcare applications

Growth Outlook

• Recent quarterly revenue increased to AUD 63,267, indicating market interest
• Strong cash position with AUD 1.44 million in cash and equivalents
• Ongoing R&D investments suggest commitment to product development and innovation

Financial Highlights

• Trailing twelve months (TTM) revenue of AUD 1.5 million reflects growth potential
• Current ratio of 6.32 indicates strong liquidity and financial health
• Net income for the latest quarter was AUD -1.26 million, showing investment in growth

Firebrick Pharma Limited operates in the drug manufacturing sector, specifically focusing on innovative treatments for respiratory conditions. The company has made significant strides in its research and development efforts, particularly with Nasodine, which has garnered attention for its potential effectiveness in treating the common cold. The growth outlook appears promising, with recent revenue figures suggesting a growing market presence. The strong cash position allows for continued investment in research and development, which is crucial for long-term sustainability and expansion. Financially, the company has demonstrated resilience, with a solid current ratio indicating that it can meet its short-term obligations. While the net income reflects ongoing investments in growth, the overall financial health remains stable, positioning Firebrick Pharma Limited as a noteworthy player in the healthcare sector.